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Protein diversityThe EPM2A gene, defective in the fatal neurodegenerative disorder Lafora disease (LD), is known to encode
two distinct proteins by differential splicing; a phosphatase active cytoplasmic isoform and a phosphatase in-
active nuclear isoform. We report here the identiﬁcation of three novel EPM2A splice variants with potential
to code for ﬁve distinct proteins in alternate reading frames. These novel isoforms, when ectopically
expressed in cell lines, show distinct subcellular localization, interact with and serve as substrates of malin
ubiquitin ligase—the second protein defective in LD. Two phosphatase active isoforms interact to form a het-
erodimeric complex that is inactive as a phosphatase in vitro, suggesting an antagonistic function for laforin
isoforms if expressed endogenously in signiﬁcant amounts in human tissues. Thus alternative splicing could
possibly be one of the mechanisms by which EPM2A may regulate the cellular functions of the proteins it
codes for.
© 2011 Elsevier Inc. All rights reserved.1. Introduction
Lafora's progressive myoclonus epilepsy or Lafora disease (LD) is a
teenage-onset and fatal form of neurodegenerative disorder [1,2]. In
addition to symptoms like epileptic seizures, progressive loss of intel-
lectual abilities, loss of muscle coordination and imperfect articula-
tion of speech, LD patients also manifest pathognomonic periodic
acid-Schiff-positive (PAS+) staining intracellular inclusion bodies
called the Lafora bodies [1,2]. Hence an abnormal glycogen metabolic
process is thought to underlie the pathogenesis in LD [1,2]. The genet-
ic basis of LD has been deciphered and characterized. LD can be
caused by defects in the EPM2A gene encoding a dual-speciﬁcity pro-
tein phosphatase named laforin, or by defects in the NHLRC1 gene
encoding an E3 ubiquitin ligase named malin [reviewed in [2]].
Laforin andmalin interact with each other and colocalize in endoplas-
mic reticulum [3,4]. Besides being a substrate to malin, laforin also
work together with malin as a complex to promote the degradation
of malin targets through the ubiquitin proteasome system [3–5].
Alternative splicing of mRNA enables generation of multiple gene
products with distinct functions from a single coding sequence. It has
been recently proposed that nearly 95% of human genes undergo al-
ternative splicing resulting in the functional complexity in the
human proteome [6]. Indeed studies have shown important function-
al roles for the spliced forms and their products both in normal and in
disease conditions [6,7]. In this regard it is interesting to note that therights reserved.EPM2A gene undergoes alternative splicing [8,9]. We and others have
reported earlier the existence of two isoforms for laforin; a major iso-
form localized in the cytoplasm, and a minor isoform that is targeted
to the nucleus as well [8,9]. We have further demonstrated that the
nuclear isoform is an inactive phosphatase, and it regulates the phos-
phatase activity of cytoplasmic isoform by interacting with it and
forming a heterodimer [10]. Here, we report the identiﬁcation and
characterization of three novel splice variants of the EPM2A gene
and their functional signiﬁcance.
2. Materials and methods
2.1. Extraction of RNA and reverse transcriptase-polymerase chain
reaction (RT-PCR) analysis
Human brain tissues (obtained from the Human Brain Bank, Na-
tional Institute of Mental Health and Neuroscience, Bangalore,
India), human cell lines (HEK293 and SHSY-5Y), and mouse tissues
were processed for RNA extraction using the RNAwiz reagent
(Ambion Inc.) as recommended by the manufacturer. For the RT-
PCR, ﬁrst strand cDNAs were synthesized from the total RNA using
ﬁrst strand cDNA synthesis kit (Fermentas Life Sciences). Transcript
speciﬁc primers (see Supplementary Table S1) were used for the ex-
pression studies.
2.2. Northern blot hybridization
The human multiple tissue northern blot membrane (Human
8-Lane MTN® Blot) was commercially obtained from Clontech
37D. Dubey et al. / Genomics 99 (2012) 36–43Laboratoreis Inc., and hybridized overnight with (α
32
P)-dCTP la-
beled DNA probe (see Supplementary Table S1). The blots were
washed ﬁnally in 0.1× SSC/0.1% SDS at 55 °C and exposed to X-ray
ﬁlm at −80 °C.
2.3. Expression constructs
Details of the expression construct for the Myc/HIS or GFP-tagged
laf331, FLAG-laf331, and Myc/His-tagged-laf331 mutant C266S are
reported in our previous study [10]. The coding region of laf152 or
POCR (type-3 transcript) was PCR ampliﬁed from cDNA and cloned
in-frame into pEGFP-N1 (laf152-GFP) or pcDNA3.1/Myc-HIS (POCR-
Myc/HIS) or N-FLAG vector using primers listed in Supplementary
Table 1. An expression construct for Myc/His-tagged laf224 was
made by amplifying laf224 from IMAGE clone IMAGE: 3829460 and
then cloning it into the pcDNA vector. For laf177, cDNA from
HEK293 cells was used to amplify the coding region and then cloned
in pcDNA to create laf177-Myc/His construct. Expression constructs
for Myc/His-tagged malin (wild-type and the mutant form) or GFP-
tagged malin (wild-type) are reported in our previous study [10].
Similarly, the shRNA-mediated knockdown constructs for malin are
reported in our previous study [5], and the efﬁciency of the knock-
down was established by immunoblot using a reporter construct
(see Supplemental Figure S3).
2.4. Cell culture, transfections, immunostaining, immunoblotting and
antibodies
Cell lines were grown and maintained in Dulbecco's modiﬁed
Eagle's medium as reported earlier [10]. Transfections were per-
formed using Polyfect transfection reagent (Qiagen) according to
the manufacturer's protocols. Wherever mentioned, 10 μM of
MG132 treatment was given to cells post transfections for 12 h.
Cells grown on gelatin coated coverslips were processed for immuno-
ﬂuorescence staining as reported previously [10]. For immunoblot-
ting, protein samples were run on a 12% SDS-PAGE, and transferred
onto a nitrocellulose ﬁlter as described [10]. After blocking, the mem-
branes were processed through sequential incubations with primary
antibody followed by horseradish peroxidase (HRP) tagged secondary
antibody and signals were visualized using a chemiluminiscent sub-
strate (SuperSignal West PICO, Thermo Scientiﬁc, USA). Antibodies
used in the present study are: rabbit anti-Myc (Cell Signaling Tech-
nology Inc), mouse anti-Myc (Sigma-Aldrich), rabbit anti-FLAG
(Sigma-Aldrich), mouse anti-GFP (Roche Applied Science), rabbit
anti-GST (Sigma-Aldrich), andmouse anti-γ-tubulin (Sigma-Aldrich).
The FITC, TRITC or HRP tagged secondary antibodies were obtained
from Jackson Immunoresearch, USA.
2.5. Pull-down assay
For Ni-afﬁnity pull down assays, cells were transfected with suit-
able tagged constructs as described [10]. Forty eight hours after trans-
fection, the cells were lysed with RIPA lysis buffer and then incubated
with EZview Red His-Select HC Nickel Afﬁnity Gel (Sigma-Aldrich
Chemicals Pvt Ltd) at 4 °C for 2 h as reported. The beads were then
washed with RIPA buffer to remove non-speciﬁc proteins. The bead
bound proteins were either used for phosphatase activity assay or
loaded on SDS-PAGE after boiling with laemmli buffer as described
[10].
2.6. Phosphatase activity assay
His-tagged proteins were puriﬁed using nickel resin and the bead
bound proteins were used for the phosphatase activity assay as de-
scribed [10]. Approximately 100 ng of puriﬁed protein was used and
the assay was performed in 75 μl reaction buffer containing 25 mMpara-nitro phenyl phosphate (pNPP; Bangalore Genei). The reaction
was incubated at 37 °C for 30 min and then stopped using 200 μl of
0.2 N NaOH. Absorbance was taken at 405 nm. Experiments were
done in triplicate and average absorbance readings were plotted in
graphs. A fraction of the bead bound protein was tested in immuno-
blot analysis.
2.7. Glycogen binding assay
For the production of glutathione S-transferase (GST)-tagged fu-
sion protein, desired constructs were expressed in E. coli and the pro-
tein was puriﬁed as described [11]. The puriﬁed proteins were then
added to the glycogen binding assay in the presence or absence of
10 mg/ml glycogen, incubated on ice for 30 min and then centrifuged
at 17,000 g for 90 min at 4 °C as described [11]. The supernatant and
pellet fractions were separated and immunoblotted with anti-GST
antibody.
3. Results
3.1. Identiﬁcation and characterization of novel splice variants of the
EPM2A gene
The EPM2A gene is known to undergo alternative splicing, result-
ing in at least two splice-variants, coding for two distinct proteins
[8,9] (referred to here as type-1 and type-2 transcripts respectively;
see Fig. 1). To identify novel splice variants of the EPM2A gene, we
searched the sequence database of NCBI for partial or complete
cDNA sequences representing the transcripts of EPM2A gene but hav-
ing unique exon organization. The AceView database (http://www.
ncbi.nlm.nih.gov/IEB/Research/Acembly/), lists 17 distinct splice var-
iants for the EPM2A gene out of which the expression status of only
two was established (referred to here as type- and type-2 transcripts;
Fig. 1). We therefore designed primers to speciﬁcally amplify each of
the splice variants that are represented by more than one indepen-
dent cDNA clones and tested their expression in the cDNA derived
from the adult human brain. Our reverse transcriptase polymerase
chain reaction (RT-PCR) assays established the expression of three
novel splice variants for the EPM2A gene, and they were named as
type-3, type-4 and type-5 respectively (see Fig. 1). The type-4 tran-
script is represented by two cDNA clones (GenBank accession #
BC005286; cDNA clones, BE268120 and BF032161), expressed in the
adult brain tissue, and is characterized by the skipping of exon 3.
Clone BC005286 harbors the poly-A tail but the 5′-end appears to
be incomplete; a sequence alignment with the full length clone of
type-1 transcript (GenBank accession # NM_005670) reveals that
BC005286 harbors the ﬁrst exon but lacks the 5′ sequence from +4
position of the coding sequence (Fig. 1). RT-PCR analysis, using
primers ﬂanking the exon 3 (F2-R4), resulted in the ampliﬁcation of
two distinct amplicons from the human adult brain cDNA (Figs. 1A
and B). The higher molecular weight amplicon represent the type-1
or type-2 transcript while the lower molecular weight amplicon rep-
resent the novel transcript type-4 lacking exon 3 in its coding se-
quence (Fig. 1B). The type-5 transcript is represented by the cDNA
with GenBank accession # AK022721 and is supported by four inde-
pendent Expression Sequence Tag (EST) clones (AU125766,
BI561221, DA920514, and AA400516). This transcript appears to
have a novel 5′-end sequence thus deﬁning a novel ﬁrst exon for
this transcript, located between the exon 2 and 3 of the type-1 tran-
script (see Fig. 1). We have used a speciﬁc forward primer from the
5′-end unique exon of the type-5 transcript region for the RT-PCR
and conﬁrmed the expression of this transcript in the adult human
brain (Figs. 1A and B). The third transcript characterized in the pre-
sent study is type-3, represented by a cDNA clone with GenBank ac-
cession # AF454494 (Fig. 1). This clone appears to lack the 5′-, and
3′-ends of the messenger as it lacked poly-A sequence as well. A
Fig. 1. Identiﬁcation of three novel transcript variants of the EPM2A gene and proteins they encode. (A) Schematic showing the known (type-1 and -2) and novel transcripts (types 3–5)
of EPM2A on the left hand side. The empty boxes represent the coding sequence of the exons while the grey boxes represent untranslated regions in the transcript. The position of
the start codon and the stop codon in the open reading frames are depicted by ATG and asterisk (*), respectively. The relative strength of the predicted start codons (Kozak
reliability score) [14] is shown close to the start codons identiﬁed as “ATG” in the schematic. The start codon shown for type-4 transcript is predicted based on type-1 transcript
since the sequence of cDNA clone lacks the 5′ sequence from +4 position of the coding sequence of type-1 transcript. The arrows below each transcript show the position of
the forward (F) and the reverse (R) primers used in the RT-PCRs (see Supplementary Table S1 for primer sequence). The small, lined boxes (identiﬁed as probe A and probe B)
below type-3 and type-1 transcripts show the positions of the probes used for the northern blot hybridization. The predicted protein products coded by these transcripts are iden-
tiﬁed on the right side (dotted arrow). The domain structure of the putative peptides predicted to code by each ORF is shown. Here, conserved domains are identiﬁed by shaded
boxes, and region that is unique to each isoform is identiﬁed by a lined box. CBD—carbohydrate binding domain; DSPD—dual-speciﬁcity phosphates domain. POCR sequence does
not harbor CBD or DSPD but shows a weak similarity API5 domain (identiﬁed by a shaded box). (B and C) Gel pictures showing the result of the RT-PCRs. Human brain tissues were
used to isolate RNA and then cDNA was synthesized. Different combinations of primer pairs (positions identiﬁed in A) were used to perform RT-PCRs as indicated. In C, the cDNA
derived from the reaction done in the presence or absence of the reverse transcriptase (RT) is indicated with “+” and “–” symbols, respectively. (D) The human multiple tissue
northern blot was hybridized with probe-A (speciﬁc to type-3 transcript) or probe-B (could detect all transcripts except type-3) as indicated. Hybridization with actin probe served
as control. The amino acid sequence of individual isoforms is given in Supplemental Figure S1.
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quence spanning the EPM2A locus reveal that this cDNA clone could
possibly represent an unspliced mRNA as it shared exact identity
with exon 1 coding region and the adjacent 649 bp novel sequence
was found to be originated from the intronic region present contigu-
ous to exon 1 (see Fig. 1A). To conﬁrm that this clone indeed repre-
sent transcribed region, northern and RT-PCR analyses were done
(Figs. 1C and D). A 214 bp fragment from the 3′-end unique region
(probe-A) yielded prominent signal at 4.4 kb position in the human
multiple tissues northern blot (Fig. 1D). Based on the sequence of
type-1 transcript, primers were designed to amplify putative 5′-
ﬂanking region and expected size fragment was detected by RT-PCR
conﬁrming the production of such a novel isoform, designated as
type-3 transcript (Fig. 1C). Since the size of the transcript detected
in the northern blot was found to be larger than the length of the
cDNA clone, it could be presumed that this transcript might harbor
additional regions not represented in the cDNA. Our repeated at-
tempts to extend the 5′- and 3′-ends of the cDNA clone using the
RACE approach did not yield any speciﬁc product. Nonetheless, the
detection of more than one band for the EPM2A gene in the northern
blot suggests the presence of multiple transcript variants (Fig. 1D).
Alternative splicing is known to be regulated by SR family proteinsby binding to the exonic splicing enhancers (ESEs) present in the con-
stitutively and alternatively spliced exons [12]. Indeed a sequence
search for ESEs for the EPM2A transcript, using the online tool ESEﬁn-
der [13] (http://rulai.cshl.edu/tools/ESE), identiﬁed 5 potential bind-
ing sites for the SR family proteins SF2/ASF, SRp40, SRP55 and SC53.
We have also tested whether such differentially spliced transcripts
for the Epm2a gene are transcribed in mouse. Primers ﬂanking indi-
vidual exons were used for the ampliﬁcation of differentially spliced
transcript by RT-PCR but none of these attempts identiﬁed addition
transcripts other than the known Epm2a transcript (Type-1 equiva-
lent) (see Supplemental Fig. S2).
In order to understand the coding potential of these novel tran-
scripts identiﬁed for the human EPM2A gene, we analyzed the poten-
tial open reading frames (ORFs) using the online tool, ATGpr (http://
atgpr.dbcls.jp/) [14], and found that ﬁve laforin isoforms can be
encoded by these three novel transcripts (Fig. 1A and Supplemental
Fig. S1). The consensus sequence of the type-3 transcript contains
two potential open reading frames (ORFs) that overlap each other
(Fig. 1A and Supplemental Fig. S1). One of them encodes a truncated
form of laforin composed of 152 amino acids containing the putative
carbohydrate binding domain (CBD) (Fig. 1A and Supplemental
Fig. S1). This truncated laforin was named as laf152, denoting its
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laf152 coding sequence, could produce an entirely distinct protein
of 344 amino acids with a molecular mass of 35 kDa (Fig. 1A and Sup-
plemental Fig. S1). POCR does not harbor CBD or DSPD (Dual-Speciﬁc-
ity Phosphatase Domain) but showed a weak similarity, in the region
aa55–135, with the pfam 05918 (E-value: 4e−05) in a CD-Domain
search of NCBI (see Fig. 2A and Supplemental Fig. S1). Pfam 05918
represents a protein family containing apoptosis inhibitory protein
5 (API5) sequences and such proteins, known in several organisms,
were shown to function as anti-apoptotic proteins [15]. Similar to
type-3, the type-4 transcript also showed two overlapping ORFs. Al-
though, the cDNA clone representing the type-4 transcript starts
from 4 nucleotides upstream of the ﬁrst exon of the type-1 transcript,
we assume here that the 5′-end of the type-4 transcript is similar to
that of the type-1 transcript. In one of the ORFs it encodes for a 224
amino acid long protein which harbors the CBD while in the other
reading frame, it could encode a small 88 amino acid long peptide
having a truncated DSPD (Fig. 1A and Supplemental Fig. S1). Unlike
the other two novel transcripts, type-5 transcript has only one ORF
wherein it codes for a 177 amino acid long protein (laf177) having
the DSPD (Fig. 1A and Supplemental Fig. S1).
We then checked the translation ability of these ORFs by expres-
sing the potential coding sequence in mammalian cell lines.
For this, we made expression constructs containing the coding
region of POCR, laf224, laf88 or laf177 with C-terminal Myc/His tag
or N-termianl FLAG tag for laf152, transiently transfected them in
COS-7 cells and then analyzed by immunoblotting (Fig. 2A). All the
constructs produced expected size proteins. However, laf88 did not
obtain any signal despite several attempts with several independent
clones. Intriguingly, the subcellular distribution of all other isoforms
was found to be distinct (Fig. 2B). Whereas the signal for POCR was
found restricted to the nucleus in a majority of the cells, laf152 and
laf224 were distributed both in nucleus and cytoplasm. On the other
hand, laf177 showed majorly cytoplasmic localization similar to
laf331 (Fig. 2B).
3.2. Novel isoform laf177 is an active phosphatase and it interacts with
laf331, laf317 and POCR
Laf331 is an active dual-speciﬁcity protein phosphatase [16] while
its isoform laf317 is an inactive phosphatase [10]. The type-5 tran-
script discovered in the present study is predicted to encode a protein
(laf177) with the dual-speciﬁcity phosphatase domain (DSPD). In
order to test whether laf177 will be active as a phosphatase or not,
we transiently expressed Myc/His tagged laf177 in COS-7 cells and af-
ﬁnity puriﬁed laf177 using Nickel resin and used the protein for an in
vitro phosphatase assay. Similarly, we expressed the wild-type laf331Fig. 2. Expression analyses of laforin isoforms: Expression constructs that code for laf331, POCR
laf152, were transiently expressed in COS-7 cells and processed for immnunoblot analysis (
These images in A represent the localization pattern of a majority of transfected cells (~80–or its catalytically inactive mutant (Laf331-C266S), puriﬁed and used
them in the phosphatase assay as positive and negative controls, re-
spectively. Around 100 ng of the bead-bound protein was incubated
with the chromogenic substrate pNPP to detect the phosphatase ac-
tivity. As shown in Fig. 3A, the novel isoform laf177 showed robust
phosphatase activity which was comparable to that of laf331. The
laf331 mutant C266S did not show any activity as expected. Thus
laf177 appears to be an active phosphatase.
We have shown earlier that the laforin isoforms laf331 and laf317
physically interact with each other and form a heterodimer that is en-
zymatically inactive [10]. Thus, to investigate the possibility that the
laf177 could form heterodimer with laf331 or laf317, we coexpressed
Myc/His tagged laf177 with FLAG tagged laf331, laf317 or laf152 and
pulled the proteins using Nickel resin, and the interaction was ana-
lyzed using an immunoblot. As shown in Fig. 3B, laf177 was able to
pull-down both laf331 and laf317 suggesting that this novel isoform
of laforin could physically interact with the two known isoforms of
laforin. Similar observations were made when POCR was coexpressed
(Fig. 3B). However, no signal was detected for laf152 in the pull-down
product, suggesting that laf177 does not interact with laf152 (Fig. 3B).
Similarly, the Nickel resin did not pull laf331 in the absence of any
His-tagged protein (Fig. 3B, last lane), thus establishing the speciﬁcity
of the assay. We next tested the phosphatase activity of laf177–laf331
or laf177–laf317 heterodimers. For this, we coexpressed Myc/His
tagged laf177 with FLAG tagged laf331 or laf317 and pulled the pro-
teins using Nickel resin (Fig. 3C). Thereafter, the resin bound protein
complex was subjected to the in vitro phosphatase assay. Intriguingly,
the phosphatase activity of the laf177–laf331 and laf177–laf317 com-
plexes was found to be lower than that of laf177 (Fig. 3C). This could
possibly mean that laf177 as a heterodimer with laf331 or laf317 is in-
active as a phosphatase. Since the complexes were pulled using the
His-tag attached to laf177, the pull-down product is likely to have
laf177 as a monomer (or as homodimer) and the laf177–laf331 or
laf177–laf317 complex as a heterodimer. Thus, the decreased activity
(~50% to that of laf177 only complex; see Fig. 3C) observed in these
two pull-down products could possibly be due to the presence of
laf177 monomer or its homodimer. This suggestion is strengthened
by the observation that the mixture having laf177–laf317 complex
also showed phosphatase activity albeit at lower level (see Fig. 3C).
Laf317 is inactive as phosphatase and the activity observed here
should have come from the laf177 monomer or its homodimer. This
suggestion is further strengthened by the observation that the level
of phosphatase active laf331 and phosphatase inactive laf317 was
similar in the laf177–laf331 and laf177–laf317 complexes respective-
ly (bars/lanes 5 and 6 in Fig. 3C) yet there was no difference in the
phosphatase activity of these two complexes. Since we were unable
to make a construct for laf177 with any other tag, we were not able, laf224, and laf177 with Myc/His tag at the C-terminal or with N-terminal FLAG tag for
A) or indirect immunoﬂuorescence analysis (B) using anti-Myc or anti-FLAG antibody.
90%). Scale, 10 μm.
Fig. 3. Phosphatase activity and glycogen binding property of laforin isoforms: (A) Expression constructs that code for Myc/His-tagged laf331, laf177, and laf331 mutant C266S or an
empty vector (pcDNA) were transiently transfected in COS-7 cells, His-tagged proteins were afﬁnity puriﬁed using Nickel resin and subjected to phosphatase assay using the chro-
mogenic substrate pNPP. Values shown are means of three independent reactions (y-axis: arbitrary vales [AV]). A fraction of the eluate was used for immunoblotting with anti-Myc
antibody to show the elution/purity (below). (B) To check the interaction between laf177 and lf33, laf317, Laf152, POCR or malin, COS-7 cells were co-transfected with Myc/His-
tagged laf177 and FLAG-tagged isoforms as indicated, and processed for the pull-down assay using the Ni-resin. The pull-down products (PD) and whole cell lysates (WCL) were
immunoblotted (IB) with anti-FLAG and anti-Myc antibodies, as indicated. Cells co-transfected with empty vector (pcDNA) served as control. (C) To check the phosphatase activity
of heterodimers of laforin isoforms, COS-7 cells were transiently transfected with the expression construct as indicated and the lysate was processed for the Ni-afﬁnity resin pull-
down assays. The resin bound proteins were used for the phosphatase assay using the pNPP as substrate. Values shown are means of three independent reactions. The purity and
expression levels of the pulled-down proteins (the bait as well as the interacting partner) in each experiment were examined by immunoblotting, as shown below the graph
(p>0.005 [*]; t-test). (D) To check the glycogen binding property of laf224 and laf152, the coding regions of these two peptides were cloned into a bacterial expression vector
to produce the protein as a fusion to the GST in E. coli. The protein was afﬁnity puriﬁed and then incubated with glycogen, centrifuged and the proteins in the glycogen pellet
(P) or the supernatant (S) fraction were visualized by western blot using anti-GST antibody. The GST protein without any fusion was used as a negative control for the assay.
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tase activity. Nonetheless, the observation that the decreased phos-
phatase activity was seen in the laf177–laf331 complex strongly
suggests that laf177 as heterodimer is inactive as a phosphatase.
3.3. Laf224 and laf152 bind to glycogen in vitro
Although both laf331 and laf317 harbor CBD, only laf331 binds to
glycogen in vitro[10]. Since the two of the novel isoforms of laforin —
laf152 and laf224, harbor CBD, we next wanted to check whether or
not these proteins bind to glycogen. For this we made an expression
construct that code for glutathione S-transferase (GST) fused with
laf152 or laf224 at the carboxyl terminal. Thereafter, we expressedGST (control) or the GST fusion protein in E. coli, puriﬁed using gluta-
thione beads, and afﬁnity of the puriﬁed proteins to the glycogen was
tested in an in vitro glycogen binding assay. Both laf152 and laf224
precipitated with glycogen and were detected in the pellet fraction
in western analysis using anti-GST antibody (Fig. 3D). As expected,
the GST protein did not bind to the glycogen (Fig. 3D).
3.4. Malin interacts with laforin isoforms and promotes their degradation
Malin and laf331 are known to interact with each other and malin
is known to promote its degradation [5]. Similar to laf331, isoform
laf317 has also been shown to interact with malin and undergo deg-
radation [10]. To check whether laforin isoforms laf152, laf177, and
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teins with distinct tags, in COS-7 cells, and processed for the pull-
down assays using Nickel resin. As shown in Fig. 3B (lane 5) and
Fig. 4A, Myc/His-tagged laf224 and laf177 were able to pull FLAG-
tagged malin, suggesting that malin physically interacts with these
isoforms. Since Myc/His-tagged construct was not available for
laf152, we coexpressed FLAG-tagged laf152 with Myc/His tagged
malin. Malin was able to pull Flag-tagged laf152. Taken together
with previous reports [5,10], it could be suggested that malin inter-
acts with all 5 isoforms of laforin that bear DSPD and/or CBD domains.
Having known that the isoforms of laforin interact with malin, we
next checked whether malin can promote the degradation of the
novel isoforms of laforin. To test this possibility, we coexpressedFig. 4. Malin interacts with and promotes the degradation of laforin isoforms: (A) To check the
cotransfected with expression constructs as indicated. The lysates were then processed for p
cell lysates (WCL) were immunoblotted (IB) with anti-FLAG and anti-Myc antibodies as ind
(last lane). (B) To check whether malin promotes the degradation of laforin isoform, expres
construct for GFP (control) or malin mutant and the cellular level of laforin isoforms was e
served as loading control. (C) As an alternate, laforin isoforms were either expressed alone or
treated (+) or not treated (−) with the proteasomal blocker MG132 as indicated. The cellu
malin or its mutant was also established by immunoblotting. Tubulin served as loading con
for laforin isoform when coexpressed with wild-type malin as compared to its level whenlaf331 and the three novel isoforms (laf224, laf177 and laf152)
along with a shRNA (RNAi) knockdown construct for malin or GFP
(control) in COS-7 cells and measured the cellular level of laforin iso-
forms by immunoblotting. The shRNA knockdown constructs are val-
idated in our previous studies [5] and controls blots are included here
to show their efﬁciency (see Supplemental Fig. S3). As shown in
Fig. 4B, knockdown of malin resulted in an increase in the signal in-
tensity for each of the four isoforms. To further conﬁrm the notion
that malin indeed promote the degradation of laforin isoforms, we
coexpressed laf224, laf177 or laf152 either with the wild-type malin
or its inactive mutant C26S and in one set of cells coexpressing iso-
forms and wild type malin were treated with the proteasomal blocker
MG132 (Fig. 4C). As a control, isoforms were expressed alone in theinteraction of malin with laforin isoforms laf152, laf224, and laf177, COS-7 cells were
ull down assays using Nickel afﬁnity resin. The pulled-down products (PD) and whole
icated. Lysate of cells transfected with an empty vector was used as a negative control
sion construct coding for laf331, laf152, laf177 or laf224 was coexpressed with an RNAi
valuated by immunoblotting, as indicated. Probing the blot with anti-tubulin antibody
with the wild type GFP-malin (WT) or with the activity mutant malin (C26S) and were
lar level of laforin isoform was established by immunoblotting (IB). The expression of
trol. Densitometric measurement conﬁrmed signiﬁcant decrease in the signal intensity
expressed with mutant malin C26S or upon MG132 treatment (data not shown).
42 D. Dubey et al. / Genomics 99 (2012) 36–43presence or absence of MG132 as well (Fig. 4C). Laf331 was also
expressed with similar combination for a comparison (Fig. 4C). In
each of these sets, the signal intensity of laforin isoform is higher
when expressed alone as compared to the one that was expressed
with wild-type malin. However when treated with MG132 or when
expressed with the mutant malin, its level was signiﬁcantly higher.
These data suggest that, as was known for laf331 and laf317 [10],
malin promotes the degradation of the novel isoforms of laforin,
laf152, laf224 and laf177, through the proteasomal system.
4. Discussion
A majority of the human genes predicted to have multiple tran-
scriptional units thereby coding for more than one gene product. Sup-
porting this notion, the present study demonstrates that EPM2A is a
gene of such complexity. Alternative splicing in EPM2A generates at
least ﬁve different transcript variants, named here as type-1 to
type-5 transcripts. These include the three novel transcripts discov-
ered and characterized in the present study (type-3, -4, and -5).
Among these, the cDNA representing the type-4 and type-5 validated
in the present study seem to have the 3′-end intact as both had the
poly-A tail. Repeated attempt to extend the 5′-end of the cDNA,
using the 5′-RACE approach did not yield any product. It may be
recalled here that the ﬁrst two reports on the discovery of the
EPM2A gene had carried the partial cDNA sequences [17,18], and
only the third report identiﬁed the 5′-end of the type-1 transcript
[16]. Thus, only one cDNA clone (LDH1 — GenBank accession #
NM_005670.3) is known to harbor the 5′-end of the reported coding
sequence of the EPM2A gene [16]. The 5′-end of the EPM2A gene is GC
rich (80%) [19]. It is therefore likely, that the sequence complexity at
the 5′-region of the EPM2A gene might limit copying of the 5′-end of
the mRNA into a cDNA and hence, almost all cDNA clones reported in
the GenBank lack exon 1 region of type-1 transcript. Nonetheless, the
discovery of the cDNA clones representing type-3 to -5 transcripts
reveals the existence of novel exons for the EPM2A gene. The
expression of all these transcripts was conﬁrmed by RT-PCR using
exon-speciﬁc primers and for the single exon transcript (type-3) by
northern hybridization using the unique exon as the probe. It may
be noted here that type-5 transcript appears to have a novel exon 1.
While the presence of an exon upstream of this region could not be
ruled out, the possibility that exons 1 and 2 of the type-1 transcript
may join with the exon-1 of type-5 transcripts is less likely. This is be-
cause primers amplifying exons 2 and 3, or exons 1-to-3 of the type-1
transcript did not yield any product that was larger than the expected
size representing the type-1 transcript. Therefore, it is likely that a
few of the EPM2A transcripts might harbor novel ﬁrst exon, suggest-
ing the presence of more than one promoter elements for the
EPM2A gene. It is possible that the alternate promoters may provide
tissue speciﬁc expression of transcripts and this has shown for several
mammalian genes [20]. While we have not tested the promoter ele-
ments, it is tempting to speculate that both alternative promoter
usage and alternative splicing may contribute to the remarkable
mRNA diversity of the EPM2A gene.
Among the transcripts characterized in the present study, the
type-3 transcript reveals an unusual genomic organization in having
two ORFs that overlap with each other. Although such features are
unusual for the eukaryotic genome, it has been predicted that approx-
imately 7% of alternatively spliced genes in humans contain dual
(multiple) coding regions [21]. Indeed, the predicted start codons of
each of the four ORFs of these transcripts have reliable Kozak score
to initiate the translation, and the transfection studies using expres-
sion constructs speciﬁc to three of the ORFs did conﬁrm that they
could possibly code for proteins. However, whether or not these tran-
scripts would use both ORFs and code for both proteins at the same
time has not been tested in the present study. Although the occur-
rence of such overlapping coding sequences are known amongviruses and are rare in mammals, few such genes have been reported
to have functional overlapping reading frames; these are p16INK4A/
p19ARF (CDKN2A) gene [22], growth hormone(GH1)/GHDTA gene
[23], the LGALS3/GALIG gene [24], the human molybdopterin
synthase (MOCS2) gene [25], XLαs(Gnas)/ALEX locus [26], XBP1
ORF1/ORF2 [27] and 4E-BP3(EIF4EBP3)/MASK-BP3ARF[28]. It has
been demonstrated for these genes, using ectopic expression
constructs, that both the ORFs are functional and that they produce
proteins having varied properties. The detection of protein products
for both ORFs for type-3 transcript in transfection studies implies an
alternative initiation of translation at different AUG codons in vivo,
which could be attributed to a leaky scanning process or an internal
entry of ribosomes [29]. We were unable to conﬁrm the endogenous
expression of laforin isoforms since antibodies that could detect the
individual isoforms are not available. Hence we have used expression
constructs for each coding region and tested its coding potential in
transient expression conditions. It may be noted here that similar ap-
proach was used in a majority of studies that documented the coding
potential of transcripts with alternative reading frames [22–28].
One of the interesting aspects of ectopically expressed laforin iso-
forms is their subcellular localization: POCR shows nuclear localiza-
tion, laf331 and laf177 are cytoplasmic, and both laf224 and laf152
are localized in nucleus as well as in the cytoplasm. Indeed, proteins
with isoforms are known to localize at different subcellular compart-
ments and play different functional roles. For example, Nek2Kinase
(NEK2) has three isoforms localized differentially, enabling it to
have both nuclear and cytoplasmic functions [30]. Differentially
spliced transcripts that encode isoforms lacking the catalytic domain
have been identiﬁed in other members of phosphatase family
[31,32] and it has been suggested that such truncated polypeptides
may either present substrate molecules to their active counterpart
or instead may protect them from dephosphorylation [31]. The ﬁnd-
ings on laf331 and laf317 in our previous study [10] ﬁt well with
the aforementioned model. The present study demonstrates that iso-
form laf177, though active on its own as a phosphatase, functions
similar to the inactive laf317 in regulating the activity of laf331 by
forming a heterodimer in vitro. The present study also establishes
that malin is a critical regulator for the laforin isoforms since malin
reduces the half-life of three novel isoforms of laforin when ectopical-
ly expressed. As suggested earlier for laf317 [10], each isoform of
laforin could regulate the cellular levels of the other isoform by pre-
senting itself as a substrate to malin and thus saving the other isoform
from degradation. Clearly further work on the synergistic and antag-
onistic functions of the two active phosphatases (laf331 and laf177)
and the physiological signiﬁcance of malin in regulating the cellular
levels should shed more light on the complex interplay between the
proteins coded by the two LD genes. Nonetheless, it should be noted
here that all these studies were performed on proteins that were ec-
topically overexpressed in cell lines and that the interpretations are
based on the assumption that these isoforms are expressed endoge-
nously in signiﬁcant amounts in human tissues. It is equally likely
that these transcripts may function as non-coding regulatory RNAs,
a possibility not tested in the present study.
Since its discovery, several groups have identiﬁed LD associated
mutations (over 50 distinct mutations) in the EPM2A gene from di-
verse populations [2]. Interestingly, the site of the mutations rather
than the type of mutations was found to show some positive correla-
tions with distinct clinical subgroups of LD in a few reports [33, 34].
Given the observations that individual exons are alternatively
skipped in EPM2A, and given the possibility that not all mutations
would affect all transcripts or their protein products, it is tempting
to speculate that the functional status of individual isoforms might
underlie some of the symptoms in LD. It would therefore be of impor-
tance to carryout prospective genotype–phenotype correlation study
to understand the possible role of alternative splicing in the clinical
symptoms of LD.
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